ArticleGastroenterology2020
Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms.
Article in Gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05570448 (Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation), which is not on this map. Cited by 109 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: A Single Center, Randomized, Sham, Controlled Trial (The AREA Study)
Who cites it
109 citing papers in PubMed, 4 syntheses or guidelines pooled it, 244 citations in OpenAlex.
- Efficacy of Baclofen as Add-on Therapy for Refractory Gastroesophageal Reflux Disease: A Meta-analysis.Journal of clinical gastroenterology · 2025Pooled it
- Concomitant hiatal hernia repair with transoral incisionless fundoplication for the treatment of refractory gastroesophageal reflux disease: a systematic review.Surgical endoscopy · 2024Pooled it
- Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Pooled it
- AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Guideline
- Application of multi-perspective nursing based on the whole-course ERAS concept during laparoscopic fundoplication in patients with PPI-dependent gastroesophageal reflux disease.African health sciences · 2025Trial
- Evaluation of Aluminum and Magnesium Absorption Following the Oral Administration of an Antacid Suspension Containing Magaldrate in Healthy Women Under Fed Conditions.Advances in therapy · 2024Trial
- Efficacy of Shugan Hewei formula combined with rabeprazole in refractory gastroesophageal reflux disease: randomized, double-blind, placebo-controlled trial.European journal of medical research · 2024Trial
- Relationships Among Type D Personality, Symptoms, Depression and Anxiety, and Quality of Life in Patients With Gastroesophageal Reflux Disease.The journal of nursing research : JNR · 2026Article
- Assessment of patient-reported symptoms in Hermansky-Pudlak syndrome.Molecular genetics and metabolism · 2026Article
- Global patterns of upper gastrointestinal cancer incidence by subtype and subsite in 2022: a population-based study.Journal of the National Cancer Center · 2026Article
- Safety outcomes in 602 GERD patients treated by RefluxStop: a multi-center real-world study from 22 centers across six European countries.Scientific reports · 2026Article
- Seeking gastroenterological services during a pandemic: lessons from a large, national, population-based survey during the COVID-19 pandemic.Journal of the Canadian Association of Gastroenterology · 2026Article
- Acid bile salt induces esophageal mucosal barrier dysfunction through miR-146a-5p-KYNU pathway in gastroesophageal reflux disease.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Comparison of Fexuprazan and Esomeprazole for the Control of Nocturnal Gastroesophageal Reflux Symptoms: A Randomized, Crossover Study.Journal of neurogastroenterology and motility · 2026Article
- Association of GERD with Sleeve Gastrectomy: An Unintended Consequence.Current diabetes reports · 2026Review
- Healthcare burden of treated gastroesophageal reflux disease among U.S. adults, 2018-2023: a pooled cross-sectional analysis of the medical expenditure panel survey.Frontiers in medicine · 2026Article
- Self-Management of Reflux-Like Symptoms: A Patient-Centered Decision-Making Approach.Digestive diseases (Basel, Switzerland) · 2026Review
- Clinical characteristics and risk factors of refractory gastroesophageal reflux disease: A multicenter cross-sectional study.World journal of gastroenterology · 2025Observational
- Effect of carbonated water on esophageal high-resolution manometry metrics: a retrospective study.BMC gastroenterology · 2025Article
- Gene-Diet interaction between FTO rs9939609 and fiber intake in relation to GERD susceptibility.Molecular biology reports · 2025Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsThere are few data on the prevalence of gastroesophageal reflux disease (GERD) in the United States. We performed a population-based study to determine the prevalence of GERD symptoms and persistent GERD symptoms despite use of proton pump inhibitors (PPIs).
methodsWe conducted the National Gastrointestinal Survey in 2015 using MyGiHealth, an app that guides participants through National Institutes of Health gastrointestinal Patient-Reported Outcomes Measurement Information System surveys. Primary outcomes were prevalence of GERD symptoms in the past and persistence of GERD symptoms (heartburn or regurgitation 2 or more days in past week) among participants taking PPIs. Population weights were applied to the data and multivariable regression was used to adjust for confounding.
resultsAmong 71,812 participants, 32,878 (44.1%) reported having had GERD symptoms in the past and 23,039 (30.9%) reported having GERD symptoms in the past week. We also found that 35.1% of those who had experienced GERD symptoms were currently on therapy (55.2% on PPIs, 24.3% on histamine-2 receptor blockers, and 24.4% on antacids). Among 3229 participants taking daily PPIs, 54.1% had persistent GERD symptoms. Younger individuals, women, Latino individuals, and participants with irritable bowel syndrome or Crohn's disease were more likely to have continued symptoms, even when taking PPIs.
conclusionsUsing a population-based survey, we found GERD symptoms to be common: 2 of 5 participants have had GERD symptoms in the past and 1 of 3 had symptoms in the past week. We also found that half of PPI users have persistent symptoms. Given the significant effect of GERD on quality of life, further research and development of new therapies are needed for patients with PPI-refractory GERD symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.